MCL1
Gene Ontology Biological Process
- cell fate determination [NAS]
- cellular homeostasis [NAS]
- extrinsic apoptotic signaling pathway in absence of ligand [IMP]
- intrinsic apoptotic signaling pathway in response to DNA damage [IBA]
- negative regulation of anoikis [IMP]
- negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [IMP]
- negative regulation of intrinsic apoptotic signaling pathway [IBA]
- positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway [IGI]
- protein transmembrane transport [TAS]
- regulation of response to DNA damage stimulus [IMP]
- response to cytokine [IDA]
Gene Ontology Molecular Function
PRKAA1
Gene Ontology Biological Process
- activation of MAPK activity [NAS]
- cell cycle arrest [TAS]
- cellular response to glucose starvation [ISS]
- cellular response to nutrient levels [ISS]
- fatty acid homeostasis [ISS]
- glucose homeostasis [ISS]
- insulin receptor signaling pathway [TAS]
- lipid biosynthetic process [ISS]
- negative regulation of TOR signaling [ISS]
- negative regulation of apoptotic process [ISS]
- negative regulation of glucosylceramide biosynthetic process [NAS]
- negative regulation of lipid catabolic process [ISS]
- positive regulation of autophagy [ISS]
- positive regulation of cholesterol biosynthetic process [NAS]
- positive regulation of gene expression [IDA]
- positive regulation of glycolytic process [ISS]
- protein phosphorylation [IDA]
- regulation of circadian rhythm [ISS]
- regulation of energy homeostasis [ISS]
- response to gamma radiation [ISS]
- response to hypoxia [NAS]
- signal transduction [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.
Identification of effective combination therapies is critical to address the emergence of drug-resistant cancers, but direct screening of all possible drug combinations is infeasible. Here we introduce a CRISPR-based double knockout (CDKO) system that improves the efficiency of combinatorial genetic screening using an effective strategy for cloning and sequencing paired single guide RNA (sgRNA) libraries and a robust statistical scoring ... [more]
Quantitative Score
- -2.685 [Confidence Score]
Throughput
- High Throughput
Ontology Terms
- phenotype: growth abnormality (HP:0001507)
Additional Notes
- CRISPR GI screen
- Cell Line:K562 (EFO:0002067)
- Experimental Setup:Timecourse
- GIST: A-phenotypic negative genetic interaction
- Library:Drug Target-CDKO CRISPRn library
- Significance Threshold: q-value<0.05
Related interactions
| Interaction | Experimental Evidence Code | Dataset | Throughput | Score | Curated By | Notes |
|---|---|---|---|---|---|---|
| MCL1 PRKAA1 | Affinity Capture-MS Affinity Capture-MS An interaction is inferred when a bait protein is affinity captured from cell extracts by either polyclonal antibody or epitope tag and the associated interaction partner is identified by mass spectrometric methods. | High | 0.9985 | BioGRID | 1192659 | |
| MCL1 PRKAA1 | Affinity Capture-MS Affinity Capture-MS An interaction is inferred when a bait protein is affinity captured from cell extracts by either polyclonal antibody or epitope tag and the associated interaction partner is identified by mass spectrometric methods. | High | 0.9972 | BioGRID | 2235679 | |
| MCL1 PRKAA1 | Affinity Capture-MS Affinity Capture-MS An interaction is inferred when a bait protein is affinity captured from cell extracts by either polyclonal antibody or epitope tag and the associated interaction partner is identified by mass spectrometric methods. | High | 0.9995 | BioGRID | 3028215 |
Curated By
- BioGRID